Eli Lilly's efsitora alfa, a once-weekly insulin, demonstrated non-inferior A1C reduction compared to daily insulin glargine in insulin-naïve adults with type 2 diabetes.
Eli Lilly's efsitora alfa, a once-weekly insulin, demonstrated non-inferiority to daily insulin in Phase 3 trials for type 2 diabetes, meeting its primary endpoint.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.